Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Kyntra Bio Inc (KYNB) P/E ratio

Alert me on P/E ratio

As of 13 November 2026, Kyntra Bio Inc (KYNB) trades at a P/E ratio of 0.1×. Over the past ten years it has ranged from 0.0× (September 2025) to 98.1× (December 2019); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of 11.4× and below the Healthcare sector median of 25.3×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.2× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.2× (0.54%)
Mar 2026 0.2× (13.21%)
Dec 2025 0.2× (15.71%)
Sep 2025 0.2× —
42 more quarters

Against its own ten years

Low 0.0× High 98.1×
Ten-year median 0.0×
Current reading's percentile 86

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on KYNB